Pyoderma gangrenosum: A review and update on new therapies - 24/04/13
Correspondence to: Steven R. Feldman, MD, PhD, Department of Dermatology, Wake Forest University School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157-1071.Abstract |
Pyoderma gangrenosum is a rare and often painful skin disease that can be unpredictable in its response to treatment. There is currently no gold standard of treatment or published algorithm for choice of therapy. The majority of data comes from case studies that lack a standard protocol not only for treatment administration but also for the objective assessment of lesion response to a specific therapy. This review provides an update to the treatment of pyoderma gangrenosum with a particular focus on new systemic therapies.
Le texte complet de cet article est disponible en PDF.Key words : adalimumab, alefacept, clinical trials, efalizumab, etanercept, infliximab
Plan
| Astellas Pharma Global Development Inc provided support for the preparation of this review. The Center for Dermatology Research is supported by an unrestricted educational grant from Galderma Laboratories LP. |
|
| Disclosure: Dr Feldman has received research, speaking, and/or consulting support from Abbott Labs, American Society for Dermatologic Surgery, Amgen, Astellas, Aventis Pharmaceuticals, Biogen, Centocor, Connetics, Galderma, Genentech, Novartis, and Roche. Dr Jorizzo has received speaking and/or consulting support from Amgen. Dr Miller, Dr Yentzer, and Ms Clark have no conflicts of interest to declare. |
|
| Reprints not available from the authors. |
Vol 62 - N° 4
P. 646-654 - avril 2010 Retour au numéro
Article précédent
- Prospective controlled clinical and histopathologic study of hidradenitis suppurativa treated with the long-pulsed neodymium:yttrium-aluminium-garnet laser
- Bassel H. Mahmoud, Emily Tierney, Camile L. Hexsel, John Pui, David M. Ozog, Iltefat H. Hamzavi
- Treatment of erythrodermic psoriasis: From the medical board of the National Psoriasis Foundation
- Misha Rosenbach, Sylvia Hsu, Neil J. Korman, Mark G. Lebwohl, Melodie Young, Bruce F. Bebo, Abby S. Van Voorhees
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?